156 related articles for article (PubMed ID: 37224752)
1. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.
El Omari N; Bakrim S; Khalid A; Abdalla AN; Almalki WH; Lee LH; Ardianto C; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Aug; 164():114886. PubMed ID: 37224752
[TBL] [Abstract][Full Text] [Related]
2. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin.
El Omari N; Lee LH; Bakrim S; Makeen HA; Alhazmi HA; Mohan S; Khalid A; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Aug; 164():114774. PubMed ID: 37224749
[TBL] [Abstract][Full Text] [Related]
5. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
[TBL] [Abstract][Full Text] [Related]
6. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
7. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
8. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.
Crisanti MC; Wallace AF; Kapoor V; Vandermeers F; Dowling ML; Pereira LP; Coleman K; Campling BG; Fridlender ZG; Kao GD; Albelda SM
Mol Cancer Ther; 2009 Aug; 8(8):2221-31. PubMed ID: 19671764
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity.
Ganai SA
Curr Top Med Chem; 2016; 16(4):427-34. PubMed ID: 26268342
[TBL] [Abstract][Full Text] [Related]
11. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat reverses HepaCAM gene expression and suppresses proliferation by increasing histone acetylation in prostate cancer.
Chen E; Liu N; Zhao Y; Tang M; Ou L; Wu X; Luo C
Gene; 2022 Jan; 808():145977. PubMed ID: 34592353
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
[TBL] [Abstract][Full Text] [Related]
14. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Greve G; Schiffmann I; Lübbert M
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
[TBL] [Abstract][Full Text] [Related]
16. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
17. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
19. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.
Singh A; Patel VK; Jain DK; Patel P; Rajak H
Oncol Ther; 2016; 4(1):73-89. PubMed ID: 28261641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]